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For historical, social, political, and religious reasons, Italy has traditionally
approached life sciences, especially those involving humans, with great
caution. The main law touching on human germline genome modifica-
tion, called Law 40/2004 “Rules on Medically Assisted Reproduction,”1
bans most “experimentation” on human embryos but, at the same time,
fails to define what an embryo is and, surprisingly, might have left the
door open to clinical application of therapies that modify the human
germline genome.
This chapter first discusses the general regulatory environment for scientific
work involving human germline genome modification. After having intro-
duced the hierarchy of norms in the Italian legal system, it considers in detail
relevant provisions of the Italian Constitution, European Union (EU) law,
international treaties ratified by Italy, and Law 40/2004. The second part of the
chapter aims at assessing whether and to what extent research using human
germline genomemodification technologies, as well as clinical applications of
such techniques, is permitted under the Italian legal system. Finally, it offers
some remarks on future perspectives.
ii the general legal system
In the Italian legal system, sources of law are arranged hierarchically. The
Constitution of the Italian Republic (Costituzione della Repubblica Italiana)2
1 Law 19, No. 40 (Rules on Medically Assisted Procreation) 2004.
2 Constitution of the Italian Republic (entered into force on January 1, 1948) (Italian
Constitution).
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is the apex of the system, the fundamental source of law providing the legal
basis for other sources, as well as for the activities of the public authority.3
International law becomes part of the Italian legal system in different ways,
depending on whether it is customary, treaty, or EU law. According to Article
10 of the Constitution, the national legal system “conforms to the generally
recognized rules of international law.” As confirmed by the Constitutional
Court, the Constitution refers to international customary rules in general, with
the exclusion of international treaties.4 International customary law prevails
over both ordinary laws and the Constitution itself, with the only exception for
the fundamental principles stated therein.5
Norms contained in treaties other than those of the EU legal system become
part of the domestic legal system through a special incorporation procedure,
by an act of Parliament.6 Although they become part of the Italian legal system
by virtue of an ordinary law, they assume a rank superior to statutory law
(ordinary laws and sub-legislative acts) but not the Constitution.7 Treaties that
have been incorporated in the Italian legal system must conform to every
article of the Constitution, not just to its core values. The Italian
Constitutional Court might be called to verify the constitutional legitimacy
of norms contained in treaties that have been ratified by Italy, with the aim to
strike a “reasonable balance between the duties flowing from international law
obligations, as imposed by Article 117.1 of the Constitution, and the safeguard-
ing of the constitutionally protected interests contained in other articles of the
Constitution.”8
As far as EU law is concerned, among the legislative acts listed under Article
288 of the Treaty on the Functioning of the European Union, regulations (as
well as decisions addressing persons other than states) are directly applicable
in all EU member states: they do not need any implementing legislation by
national parliaments. Directives and decisions addressing states, on the con-
trary, require national parliaments to enact proper legislation for implementa-
tion. Be that as it may, both directives and decisions might still have direct
3 In particular, constitutional law and laws of constitutional reform; ordinary law, law decree and
legislative decree; regional law; government regulations; habit or custom.
4 Constitutional Court Judgment Nos. 15/1996, 348/2007 and 349/2007.
5 Constitutional Court Judgment No. 48/1979, para. 3.
6 The so-called order of execution (ordine di esecuzione) is contained in an ordinary law
requiring the implementation of the treaty.
7 These conclusions are based on the interpretation of Art. 117.1 of the Italian Constitution,
providing that “[l]egislative powers shall be vested in the State and the Regions in compliance
with the Constitution and with the constraints deriving from EU legislation and international
obligations”; Constitutional Court Judgment Nos. 348/2007 and 349/2007.
8 Constitutional Court Judgment No. 349/2007, para. 4.7.
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effects to the extent they impose an unconditional and sufficiently clear and
precise obligation on member states, for instance when they create individual
rights which national courts must protect.9
Crucially, EU law has primacy over Italian law. Not only must Italian law
be interpreted consistently with it, but, as confirmed by the Italian
Constitutional Court, Italian judges must set aside domestic law, whenever
incompatible with EU law.10 The only exception to the primacy of EU law is
a subset of fundamental principles and constitutional rights, the core values of
the Italian legal system, which can never be breached by EU law.11 In case of
conflict between EU law and these fundamental principles, the Italian
Constitutional Court will exercise its power to verify the constitutional legiti-
macy of the EU law and might set it aside to give precedence to the
Constitution.12
iii regulatory environment
1 Constitution of the Italian Republic, EU Law, and Treaties
Human germline genome modification technologies, which have enormous
therapeutic potential, can further certain values enjoying a constitutional status
under the Italian legal system, such as the promotion of scientific progress and
the protection of health. In fact, according to the Constitution, Italy “promotes
the development of culture and of scientific and technical research”13 and
“safeguards health as a fundamental right of the individual and as a collective
interest.”14 Both are to be considered core values of the Italian legal system.
The right to science and the right to health are also guaranteed under the
International Covenant on Economic, Social and Cultural Rights (ICESCR),
which Italy ratified in 1978.15 Article 12 provides “the right of everyone to the
9 R Adam, A Tizzano, Manuale di Diritto dell’Unione Europea (Giappichelli 2017) 173–183.
10 Constitutional Court Judgment No. 170/1984, Granital. The Court has based its conclusions
on the interpretation of Art. 11 of the Italian Constitution, allowing limitations of sovereignty
that may be necessary to participate in international organizations aiming at ensuring peace
and justice among nations.
11 Constitutional Court Judgment Nos. 168/1991 and 115/1993.
12 This position has been confirmed by the Court of Justice of the European Union in the
Judgment of December 5, 2017 (Grand Chamber), case C-42/17M.A.S. and M.B (Taricco II),
released upon the request for a preliminary ruling from the Italian Constitutional Court
(Order No. 24/2017).
13 Italian Constitution, art. 9.
14 Ibid., art. 32.
15 International Covenant on Economic, Social and Cultural Rights (adopted
16 December 1966, entered into force January 3, 1976) 999 UNTS 3 (ICESCR).
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enjoyment of the highest attainable standard of physical and mental health,”
while Article 15 enshrines the right “to enjoy the benefits of scientific progress
and its applications,” as well as the “the freedom indispensable for scientific
research and creative activity.” The right to health is recognized in numerous
international instruments and has already been the object of exhaustive
elaboration (including in the General Comment No. 14,16 adopted by the
Committee on Economic, Social and Cultural Rights in 2000). On the
contrary, the contents of the right to science are still debated and its centrality
in the human rights discourse is rarely invoked. However, as stressed by the
Special Rapporteur in the Field of Cultural Rights, Ms. Farida Shaheed,
“scientific innovations are changing human existence in ways that were
inconceivable a few decade ago.”17 Science not only offers solutions to indi-
vidual, social, economic, and developmental issues, but it also has an auton-
omous standing among other fundamental rights. The meaning of science,
thus, is not just instrumental to the realization or improvement of other rights,
it has also an inherent value strictly linked to the idea of dignified human life
that goes beyond survival and security needs.18
While aGeneral Comment on Article 15 of the ICESCR is being drafted, some
indications on the normative content of the right come from the above-mentioned
report by the Special Rapporteur, as well as from the Venice Statement on the
Right to Enjoy the Benefits of Scientific Progress and Its Applications.19 In parti-
cular, the definition of the scope of the right to enjoy the benefits of scientific
progress and its applications is of key relevance for the purposes of the present
study. In this regard, it is useful to insist on two specific points.
First, the expression “benefits of scientific progress” makes it clear that these
benefits “encompass not only scientific results and outcomes but also the
scientific process, its methodologies and tools.”20 In other words, even the
16 Committee on Economic, Social and Cultural Rights, “General Comment No. 14 – The
Right to the Highest Attainable Standard of Health (Art. 12)” (August 11, 2000) E/C.12/2000/4.
17 HRC “Report of the Special Rapporteur in the Field of Cultural Rights, Farida Shaheed on
the Right to Enjoy the Benefits of Scientific Progress and its Applications” (14 May 2012) A/
HRC/20/26, para. 1 (Report of the Special Rapporteur in the Field of Cultural Rights).
18 L Shaver, “The Right to Science: Ensuring that Everyone Benefits from Scientific and
Technological Progress” (2015) 411 Journal européen des droits de l’homme – European
Journal of Human Rights 416.
19 The Venice Statement on the Right to Enjoy the Benefits of Scientific Progress and its
Applications is the outcome of three expert meetings held between June 2007 and July 2009
under the auspices by UNESCO in collaboration with the Amsterdam Centre for
International Law, the Irish Centre for Human Rights, and the European Inter-University
Centre for Human Rights and Democratization (Venice Statement) www.aaas.org/sites/defa
ult/files/VeniceStatement_July2009.pdf accessed February 27, 2018.
20 Venice Statement, para. 8.
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general enhancement of the conditions for further scientific activity is to be
considered a benefit. This is a key issue as it permits to stress that basic research
also, and not only applied research, is covered by the right to science.
Second, the term “enjoyment” has to be considered as covering not only the
dissemination of the outcomes of the scientific progress21 but also the partici-
pation in its development. This has been confirmed by the Special Rapporteur
in the Field of Cultural Rights, who stated that the normative content of the
right envisaged under Article 15 of the ICESCR includes, along with the
“access to the benefits of science by everyone, without discrimination,”
the “participation of individuals and communities in decision-making” and
also “opportunities for all to contribute to the scientific enterprise and freedom
indispensable for scientific research.”22
Thus, any total ban of research on human germline genome modification
techniques would certainly imply a violation of Article 15 of the ICESCR,
interfering with scientific progress and impairing the right of many people to
enjoy the benefits of science and its applications.
However, as the debate over the human germline genome modification
demonstrates, while the benefits of intervening on gametes or on early-stage
embryos to treat genetic diseases are evident, there is also fear that germline
modifications might leave room for abuses.23 For example, human germline
genome modification techniques could be used to enhance traits with no
therapeutic need. This generates “a public discomfort [. . .] whether for fear of
exacerbating social inequities or of creating social pressure for people to use
technologies they would not otherwise choose.”24 Moreover, along with other
genetic technologies, human germline genome modification might be con-
sidered as having an implicit and inherent eugenic nature. Eugenics, as such,
21 The access to scientific knowledge, even in the form of right to science education, is a pivotal
aspect of the right to science and it is also a precondition for its full realization, as well as for the
concrete possibility to make informed decisions. Report of the Special Rapporteur in the Field
of Cultural Rights (n 17) para. 27; Ibid. para. 22.
22 Ibid. para. 25.
23 J Sugarman, “Ethics and Germline Gene Editing” (2015) EMBO reports http://embor
.embopress.org/content/16/8/879 accessed 27 February 2018; T Ishii, “Germline Genome-
Editing Research and its Socioethical Implications” [2015] 21:8 Trends in Molecular Medicine
473; T Ishii, “Reproductive Medicine Involving Genome Editing: Clinical Uncertainties and
Embryological Needs” (2017) 27 Reproductive BioMedicineOnline www.rbmojournal.com/arti
cle/S1472-6483(16)30549-1/fulltext accessed 27 February 2018; MHPorteus, CTDann, “Genome
Editing of the Germline: Broadening the Discussion” (2015) 23:6 Molecular Therapy 980;
KS Bosley and others “CRISPR Germline Engineering – The Community Speaks” (2015) 33
Nature Biotechnology 478.
24 National Academies of Science, Engineering and Medicine, Human Genome Editing.
Science, Ethics, and Governance (National Academies Press 2017) 9.
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“is concerning because it could be used to reinforce prejudice and narrow
definitions of normalcy in our societies.”25 It “sends a message about the
‘fitness’ of [certain] traits or conditions, thereby reflecting on the worth and
value of people who have that trait in our society.”26
Eugenic practices, and in particular “those aiming at the selection of
persons,” are explicitly prohibited under Article 3.2 of the Charter of
Fundamental Rights of the European Union,27 which affirms the right to
the integrity of the person in the fields of medicine and biology. In the
Italian legal system, the Charter has the same value as EU treaties and enjoys
primacy over Italian law. According to the explanations attached to the
Charter, Article 3.2 refers to “possible situations in which selection pro-
grammes are organized and implemented, involving campaigns for steriliza-
tion, forced pregnancy, compulsory ethnic marriage among others, all acts
deemed to be international crimes in the Statute of the International Criminal
Court adopted in Rome on 17 July 1998.”28 The drafters of the EU Charter,
thus, had the intention to ban projects aimed at the improvement of the
human race based on the selection by the State of who can procreate. They
meant to ban “traditional” applications of eugenics, one that harks back to the
horrors of World War II. However, concerns about a potential new method of
selection, realized through genome manipulation, are not completely ill-
founded. Future parents are now in a position to know in advance the genetic
makeup of their children, and human germline genome modification could
therefore open the door to the “production” of “designer babies,” with parents
making decisions about their children’s genes in view of an improvement that
goes beyond the treatment of medical disorders. Indeed, to some extent, these
technologies allow a new form of eugenics, transforming parents from “vic-
tims” of a State’s impositions to be “responsible” for choices imposed on their
children.29
25 KE Ormond and others, “Human Germline Genome Editing” (2017) 101 Am J Hum Genet
167, 171.
26 Ibid. 172.
27 Charter of the Fundamental Rights of the European Union (ratified December 7, 2000,
entered into force December 1, 2007) (2000) OJ C 364/1.
28 Explanations Relating to the Charter of Fundamental Rights (2007) OJ C 303. Although they
do not have the status of law, the explanations are considered a valuable tool of interpretation
intended to clarify the provisions of the Charter.
29 C Campiglio, “Eugenetica e diritto internazionale” in N Boschiero (ed.), Ordine internazio-
nale e valori etici: VIII Convegno, Verona, 26–27 giugno 2003 (Editoriale Scientifica 2004) 453,
461. See also DJ Galton, “Eugenics: Some Lessons from the Past” (2005) 10:1 Reproductive
BioMedicine Online 133 www.rbmojournal.com/article/S1472-6483(10)62222-5/pdf accessed
February 27, 2018; JN Missa, “From State Eugenics to Private Eugenics” (1999) 13:4 Best
Practice & Research Clinical Obstetrics & Gynaecology 533.
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However, such a controversial issue has to be contextualized. Human
germline genome modification needs to be discussed in a more comprehen-
sive framework, including all the possible techniques potentially determining
a selection of individuals, and keeping in mind human rights. This is the
approach followed by the European Court of Human Rights (ECtHR) in the
caseCosta and Pavan v. Italy.30 In that case, the Court was called to decide on
the compatibility of Italy’s ban of preimplantation genetic diagnosis (PGD)
with the European Convention. In its decision, the Court stressed that con-
cerns regarding “eugenic” uses of PGD would not be sufficient to justify
banning it. Selectivity is not just a distinctive element of PGD, and therefore
it does not represent a sufficient reason to exclude its applicability. This
position was subsequently confirmed by the Italian Constitutional Court in
Judgment No. 96/2015.31
Amore explicit limit to human germline genome modification comes from
the Convention for the Protection of Human Rights and Dignity of the
Human Being with Regard to the Application of Biology and Medicine,
adopted within the Council of Europe in 1997 (also known as the Oviedo
Convention).32 Article 13 of the Oviedo Convention entitled “interventions on
the human genome” reads as follows: “An intervention seeking to modify the
human genome may only be undertaken for preventive, diagnostic or ther-
apeutic purposes and only if its aim is not to introduce any modification in the
genome of any descendants.”33 The provision, along with others contained in
Chapter IV on the “human genome,” is clearly inspired by the precautionary
principle and it is strictly connected to the “slippery slope argument”
30 European Court of Human Rights Costa and Pavan v. Italy (2012) application no. 54270/
10, para 63. For a more detailed analysis: L Poli, “La diagnosi genetica pre-impianto al
vaglio della Corte Europea dei diritti dell’uomo” (2013) 1 Rivista di Diritto Internazionale
119; L Poli, “Pre-implantation Genetic Diagnosis under the European Court of Human
Rights’ Review: An Opening toward a Wider Acceptance of the Technique in Europe?”
(2013) 4 CYIL 141.
31 Constitutional Court Judgment No. 96/2015, declaring the unconstitutionality of Art.
1.1, 1.2, and 4.1 of Law No. 40/2004. According to the Court, the exclusion of fertile
people carriers of transmittable genetic diseases from medically assisted reproduction
technology was in breach of Art. 3 of the Constitution, guaranteeing the principle of
equality. The Court found that this exclusion unreasonably balanced the interests at
stake and violated the criterion of reasonableness of the legal order, considering that
while Law 40/2004 prohibited women from acquiring information about the embryo
through preimplantation genetic diagnosis, any fetus affected by genetic disease could
be legally aborted.
32 Convention for the Protection of HumanRights andDignity of theHumanBeing with Regard
to the Application of Biology and Medicine (adopted April 4, 1997, entered into force
December 1, 1999) ETS 164 (Oviedo Convention).
33 Ibid., art. 13.
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developed in bioethics.34 As the Explanatory Report of the Oviedo
Convention makes clear, the provision aims at addressing the fear that misuse
of the progress of science in the field of genome editing “may endanger not
only the individual but the species itself,” through the “intentional modifica-
tion of the human genome so as to produce individuals or entire groups
endowed with particular characteristics and required qualities.”35 Although
from a bioethical perspective germline editing is widely perceived as
a technology that might “cross a line many have viewed as ethically
inviolable,”36 it remains unclear to what extent an intervention seeking to
impede the transmission of a serious disease would “endanger the species
itself” as mentioned in the Explanatory Report. The fear of potential eugenics
drifts is traceable in the provision, along with the uncertainty surrounding the
balance between risk and benefits connected to the application of human
germline genome modification techniques.
Be that as it may, the Oviedo Convention is not currently binding for Italy.
Although the Italian Government signed it, and authorization to ratification
was given by the Parliament with Law 145/2001, it was never ratified.37
Granted, Article 18 of the 1969 Vienna Convention on the Law of Treaties
contains an obligation not to defeat the object and purpose of a treaty prior to
its entry into force.38 This “pre-conventional obligation” is a key principle of
international law, being the expression of “good faith taken in the sense of
34 IR Pavone, La Convenzione europea sulla biomedicina (Giuffrè Editore 2009) 72–73. See also
R Andorno “The Oviedo Convention: A European Legal Framework at the Intersection of
Human Rights and Health Law” (2005) 2:4 JIBL 133.
35 Explanatory Report to the Convention for the Protection of Human Rights and Dignity of the
Human Being with Regard to the Application of Biology and Medicine: Convention on
Human Rights and Biomedicine (1997) European Treaty Series No. 164, para. 89.
36 National Academies of Science, Engineering and Medicine, Human Genome Editing (n 24)
7; Parliamentary Assembly of the Council of Europe Recommendation 2115: The Use of New
Genetic Technologies in Human Beings (October 12, 2017) (Parliamentary Assembly of the
Council of Europe, The Use of New Genetic Technologies in Human Beings).
37 Law No. 145 /2001, “Ratification and implementation of the Council of Europe Convention
for the Protection of Human Rights and Dignity of the Human Being with regard to the
Application of Biology and Medicine: Convention on Human Rights and Biomedicine,
adopted in Oviedo on 4 April 1997, as well as the Additional Protocol of 12 January 1998,
n. 168, on the prohibition of cloning of human beings” (Ratifica ed esecuzione della
Convenzione del Consiglio d’Europa per la protezione dei diritti dell’uomo e della dignità
dell’essere umano riguardo all’applicazione della biologia e della medicina: Convenzione sui
diritti dell’uomo e sulla biomedicina, fatta a Oviedo il 4 aprile 1997, nonché del Protocollo
addizionale del 12 gennaio 1998, n. 168, sul divieto di clonazione di esseri umani).
38 Vienna Convention on the Law of Treaties (adopted May 23, 1969, entered into force
January 27, 1980) 1155 UNTS 331. Art. 18 reads as follow: “A State is obliged to refrain from
acts which would defeat the object and purpose of a treaty when: (a) It has signed the treaty or
has exchanged instruments constituting the treaty subject to ratification, acceptance or
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protection of legitimate expectations of a minimal loyal behavior.”39 One
could argue that, even in the absence of a ratification, Italy is called none-
theless to act consistently with the object and purpose of the Oviedo
Convention, namely “the protection of the dignity and identity of all human
beings and the guarantee for everyone, without discrimination, of the respect
for integrity and other rights and fundamental freedoms with regard to the
application of biology and medicine.”40 However, the indeterminacy of the
notion of “human dignity,” which not only is unsatisfactorily explained in
the Explanatory Report41 but is also hardly definable as an objective value,
taking the shape of “a right of humanity,”42 does not allow us to conclude that
human germline genome modification applications per se are contrary to the
object and purpose of the Oviedo Convention.
In sum, while international law seems to pose concrete limitations to the
development and application of human germline genome modification,
a deeper analysis demonstrates that the need to avoid misuses of these techni-
ques is not incompatible with an opportune regulation of these methods. This
is also the approach recently taken by the Council of Europe. In October 2017,
the Parliamentary Assembly of the Council of Europe adopted a resolution
recognizing that, while the Oviedo Convention prohibits intervention on
germline genome, nothing precludes a possible amendment of the treaty, to
be implemented in line with the obligation contained in Article 28 of the
Convention, under which States parties must ensure that “the fundamental
questions raised by the developments of biology and medicine are the subject
of appropriate public discussion in the light, in particular, of relevant medical,
social, economic, ethical and legal implications, and that their possible
approval, until it shall havemade its intention clear not to become a party to the treaty; or (b) It
has expressed its consent to be bound by the treaty, pending the entry into force of the treaty
and provided that such entry into force is not unduly delayed”. ODörr, “Art. 18. Obligation not
to defeat the object and purpose of a treaty prior to its entry into force,” in O Dörr and
K Schmalenbach (eds.) Vienna Convention on the Law of Treaties: A Commentary (Springer
2018) 243.
39 R Kolb, Good Faith in International Law (Hart Publishing 2017) 43.
40 Oviedo Convention, art. 1.1.
41 The Explanatory Report does not provide a definition of “human dignity,” rather it focuses on
the extension of the protection, in particular stressing, at para 19, that “[t]he Convention (. . .)
uses the expression ‘human being’ to state the necessity to protect the dignity and identity of all
human beings. It was acknowledged that it was a generally accepted principle that human
dignity and the identity of the human being had to be respected as soon as life began.”
42 P De Sena, “Dignità umana in senso oggettivo e diritto internazionale” (2017) Diritti umani
e diritto internazionale 573. See also C McCrudden, “Human Dignity and Judicial
Interpretation of Human Rights” (2008) 19:4 EJIL 655; P Sykora, A Caplan, “Germline
Gene Therapy is Compatible with Human Dignity” [2017] 18 EMBO reports 2086.
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application is made the subject of appropriate consultation.”43 Additionally,
the Parliamentary Assembly, while urging “member States which have not yet
ratified the Oviedo Convention to do so without further delay, or, as
a minimum, to put in place a national ban on establishing a pregnancy with
germline cells or human embryos having undergone intentional genome
editing,” has also explicitly encouraged the development of a common reg-
ulatory and legal framework to balance “potential benefits and risks of these
technologies aiming to treat serious diseases, while preventing abuse or
adverse effects of genetic technology on human beings.”44
An opportune regulation would be therefore in line with international
sources calling for caution toward possible misuses of the techniques and
would represent at the same time a full realization of the right to science as
provided for both in the ICESCR and in the Italian Constitution.
2 Law 40/2004 on Rules on Medically Assisted Reproduction
In Italy there is no law regulating human genome modification per se.45
However, there is a law ruling on medically assisted reproduction (Law 40/
2004), which is relevant for human germline genome editing because it
regulates research on “human embryos.” The key provision of Law 40/2004
is Article 13, entitled “Experimentations on Human Embryos.” It reads:
1. Experimentations on human embryos are prohibited.
2. Clinical and experimental research on human embryos is permitted
provided it pursues only therapeutic and diagnostic purposes, aimed at
protecting the health and development of the embryo itself, and where
alternatives are not available.
3. The following are in any case prohibited: a) the production of human
embryos for research or experimentation purposes or in any case for purposes
other than the one set by this law; b) any form of eugenic selection of embryos
and gametes or interventions that, through selection techniques, manipula-
tion or artificial procedures, aim at altering the genetic heritage of the embryo
43 Oviedo Convention, art. 28.
44 Parliamentary Assembly of the Council of Europe, The Use of New Genetic Technologies in
Human Beings (n 36) para 5.
45 However, Article 81 “Quinquies” of the Industrial Property Code – Legislative Decree No. 30
of 10 February 2005 “Codice della proprietà industriale, a norma dell’articolo 15 della legge 12
dicembre 2002, n. 273” (Code of industrial property, in accordance with Article 15 of Law No.
273 of December 12, 2002) states that procedures for modifying the germline genetic identity of
the human being are excluded from patentability, and thus, from commercial exploitation. It
implements Directive 98/44/EC of the European Parliament and of the Council of July 6,
1998 on the legal protection of biotechnological inventions [1998] OJ L213/13.
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or the gamete, or set genetic features, with the exception of interventions for
diagnostic and therapeutic purposes, as per paragraph 2 of this article; c)
cloning by nucleus transfer or early embryo splitting or ectogenesis whether
for procreative or research purposes; d) the fertilization of a human gamete
with a gamete of different species and the production of hybrids or
chimeras.
4. The violation of the prohibitions referred to in paragraph 1 shall be
punished with imprisonment from two to six years and with a fine ranging
from 50.000 to 150.000 euros. In the case of violation of one of the prohibi-
tions referred to in paragraph 3, the penalty is increased. Mitigating circum-
stances cannot be considered equivalent or prevalent on the aggravating
circumstances envisaged by paragraph 3.
5. Healthcare professionals who are found guilty of one of the offenses
referred to in this article are suspended from exercising their profession for
a term between one to three years.
Law 40/2004, approved after an intense debate not only in the
Parliament but also within civil society, filled a significant normative
gap.46 It also opened “a Pandora’s box of ethical and technical issues,”47
fueling an already intense debate over challenging and sensitive issues.
Rather than providing clear directions for the application of medically
assisted reproduction techniques, it just aimed at strictly restraining their
use. It posed limits on the number of embryos that could be created at any
one time and banned embryo cryopreservation, as well as technologies
using a third party and PGD of the embryos. Eventually and unsurpris-
ingly, the Italian Constitutional Court found several of its provisions
unconstitutional,48 while the ECtHR declared the prohibition of PGD
46 JA Robertson, “Protecting Embryos and Burdening Women: Assisted Reproduction in Italy”
(2004) 19:8 Human Reproduction 1693; A Boggio, “Italy Enacts New Law on Medically
Assisted Reproduction” (2005) 20:5 Human Reproduction 1153; I Riezzo and others, “Italian
Law on Medically Assisted Reproduction: Do Women’s Autonomy and Health Matter?”
(2016) 16 BMC Women’s Health 44.
47 V Fineschi and others, “The New Italian Law on Assisted Reproduction Technology (Law 40/
2004)” (2005) 31 Journal of Medical Ethics 536, 539.
48 The Constitutional Court, with Judgment No. 151/2009, has declared unconstitutional Art.
14.2 (insofar as it imposed the creation of a limited number of embryos – maximum of three –
and the duty to implant them simultaneously in utero), and Art. 14.3 (insofar as it did not
provide that the transfer of the embryos should be made without prejudice to the health of the
woman). With Judgment No.162/2014, the Court has then declared unconstitutional Art. 4.3,
Art. 9, sections 1 and 3 (limited to the phrase “in breach of the prohibition laid down by Article
4.3”), and Art. 12.1, insofar as they ruled out recourse to heterologous techniques in the event of
medically established sterility or infertility. Finally, Judgments Nos. 96/2015 and 229/2015
(n 31) considered the exclusion of fertile people carriers of transmittable genetic diseases from
medically assisted reproduction technology.
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in violation of Article 8 of the European Convention on Human Rights in
the case Costa and Pavan v. Italy.49
In Judgment 229/2015, the Constitutional Court declared the unconsti-
tutionality of Articles 13.3.b and 13.4 because they criminalized the
selection of embryos even when it is aimed at avoiding the implantation
of embryos affected by genetic transmissible diseases that meet the sever-
ity criteria set forth in Article 6.1.b of the Law 194/1978 regulating
abortion.50 This decision was consistent with the conclusions reached in
its previous Judgment 96/2015 and by the European Court in the case
Costa and Pavan.
However, on the question of the ban on research on cryopreserved
supernumerary embryos, both the Italian Constitutional Court and the
ECtHR have been less trenchant. First, in Parrillo v. Italy, in the light of
a lack of European consensus on the matter, the European Court recog-
nized that States have a wide margin of appreciation on this sensitive
issue. Thus, it ruled out that such prohibition violates Article 8 of the
European Convention.51 Then, in Judgment 84/2016 the Constitutional
Court rejected as inadmissible a request of a ruling on the constitution-
ality of the ban, issued by the Tribunal of Florence on December 7, 2012.
In the decision, the Constitutional Court affirmed that it is within the
powers of the legislator, “acting as the interpreter of the general will, . . . to
strike a balance through legislation between the fundamental values that
are in conflict, taking account of the views and calls for action that it
considers to be most deeply rooted at any given moment in time within
the social conscience.”52
After these two decisions, Article 13 of the Law 40/2004 remains an extre-
mely ambiguous provision as far as genome editing is concerned. On the one
hand, the Article prohibits experimentations on embryos in general terms
(paragraph 1) and explicitly bans interventions that, “through selection tech-
niques, manipulation or artificial procedures, aim at altering the genetic
heritage of the embryo or the gamete, or set genetic features” (paragraph 3).
On the other hand, it leaves the door open for possible diagnostic or ther-
apeutic application of gene editing (paragraphs 2 and 3).
49 Costa and Pavan v. Italy (n 30).
50 LawNo. 194/1978 “Rules for the social protection of motherhood and voluntary termination of
pregnancy” (Norme per la tutela sociale della maternità e sull’interruzione volontaria della
gravidanza).
51 European Court of Human Rights, Parrillo v. Italy (2015) application no. 46470/11, para
174–176.
52 Constitutional Court Judgment No. 84/2016, para 11.
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3 The Opinion on Ethical Considerations Surrounding
Gene Editing and CRISPR-CAS9 Technique of the National
Committee for Bioethics
The overview of the Italian regulatory framework would not be complete
without mentioning the Opinion on Ethical Considerations Surrounding
Gene Editing and CRISPR-CAS9 Technique, released by the Italian
Committee for Bioethics (Comitato Nazionale per la Bioetica – ICB) on
February 23, 2017 (“2017 Opinion”).53 The ICB was established in 1990 by
the Council of Ministers, with the task of advising the Presidency of the
Council of Ministers, and even drafting laws, on ethical and legal problems
arising out of advances in biological scientific research and technological
applications.54 While ICB documents are not per se binding, they contribute
to stimulate and drive political and legal debate over ethically controversial
issues.
In its 2017 Opinion, the Committee expresses its favor for animal experi-
mentation (as long as it is performed according to international rules) with the
aim to test the safety and effectiveness of gene editing on germline and
embryos.55 While encouraging research on gene editing on human somatic
cells,56 the Committee unanimously rejects experimentation on gametes that
are intended to be used in reproduction and on human embryos to be
implanted.57
With regard to gene editing on gametes that are not to be used in reproduc-
tion and/or on embryos that are not to be implanted, the Committee’s
members are split. One view is that the moratorium on clinical research
should not be extended to in vitro basic research on these gametes and
embryos because this would mean “precluding research aiming at improving
[gene editing]” and because the findings of this research are necessary to assess
the scientific feasibility and ethical acceptability of clinical applications in the
future.58 The other view is that basic research is not currently justified,
considering that, from a clinical perspective, gamete selection is preferable
to gamete editing and that assessing the effectiveness and safety of in vitro gene
53 Italian Committee for Bioethics (ICB), “L’editing genetico e la tecnica CRISPR-CAS9:
considerazioni etiche” (February 23, 2017). http://bioetica.governo.it/it/documenti/pareri-e-ris
poste/l-editing-genetico-e-la-tecnica-crispr-cas9-considerazioni-etiche accessed July 31, 2018.
54 National Committee for Bioethics http://bioetica.governo.it/it accessed July 31, 2018.
55 Ibid. para. 4.1.
56 Ibid. para. 4.2.
57 Ibid. para. 5.
58 Ibid. para. 5.1. This is the position of nine members of the Committee (Professors Battaglia,
Canestrari, Casonato, de Curtis, Di Segni, Flamigni, Garattini, Toraldo di Francia, Zuffa).
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editing on embryos is not possible, since results of the genetic modification
can be assessed only at birth or even later.59
4 Oversight Bodies for Research on Human Germline Modification
In Italy, a number of bodies oversee biomedical research. Governmental
bodies include the Ministry of Health (Ministero della Salute) and the
Ministry of University and Scientific Research (Ministero dell’Universitá
e della Ricerca Scientifica).
Additionally, a number of independent bodies (Comitati Etici) have been
established in universities, in public health facilities and in the so-called
healthcare research institutes (Istituti di ricovero e cura a carattere scienti-
fico), where clinical research activities are carried out. While the organiza-
tional set up of Committees varies from region to region, all Committees are
called to evaluate and approve clinical trial protocols. In addition, their
powers extend to issues concerning the use of medicinal products and
medical devices as well as of surgical and clinical procedures.60 In more
detail, according to Article 1 of Ministry of Health Decree of February 8,
2013, the Ethics Committees
1. [. . .] have the responsibility to ensure the protection of the rights, safety and
well-being of people taking part to experimentations and to provide public
guarantees of such protection.
2. Where not already assigned to specific bodies, ethics committees can
also perform advisory functions in relation to ethical issues related to scien-
tific and welfare activities, in order to protect and promote fundamental
values. The ethics committees, moreover, can propose training initiatives
for health personnel regarding issues related to bioethics.61
The general framework of Ethics Committees has been modified in time.
The most recent reform took place in 2018 when Law 3/201862 reduced the
59 Ibid. para. 5.2. This is the position of nine members of the Committee (Professors Amato,
Caltagirone, Dallapiccola, D’Agostino, Gensabella, Morresi, Palazzani, Proietti, Scaraffia).
60 Law No. 189 /2012 “Conversion into law, with amendments, of the law decree n. 158 of
13 September 2012, containing urgent provisions to promote the development of the country
through a higher level of health protection” (Conversione in legge, con modificazioni, del
decreto-legge 13 settembre 2012, n. 158, recante disposizioni urgenti per promuovere lo sviluppo
del Paese mediante un più alto livello di tutela della salute), art 12.10.c.
61 Ministry of Health Decree of February 8, 2013, “Criteria for the composition and functioning
of ethics committees” (Criteri per la composizione e il funzionamento dei comitati etici).
62 Law No. 3/2018, “Delegation to the Government in the matter of clinical trials of medicines,
containing provisions for the reorganization of the health professions and for the health
leadership of theMinistry of Health” (Delega al Governo in materia di sperimentazione clinica
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number of the Committees to a maximum of 40 throughout the country and
established the “National Coordinating Center for Territorial Ethics
Committees” (Centro di coordinamento nazionale dei comitati etici territor-
iali), with the mission to coordinate, guide, and monitor the activities of all
Ethics Committees. In exceptional cases, the National Coordination Center
might be involved in the evaluation of studies requiring a review for security
reasons.
Finally, as already mentioned, the Italian Committee for Bioethics might
provide opinions on ethical and legal problems arising out of advances in
biological scientific research and technological applications.
Still, despite the existence of numerous entities with oversight
competences, there are no governmental or nongovernmental bodies
explicitly tasked to monitor research involving human genome editing
per se.
5 Funding Opportunities
At this point in history, research on human germline genome modification
cannot be funded with public money. It cannot be funded with EU money
either. EU Regulation No. 1291/2013,63 establishing “Horizon 2020,” the
Framework Programme for Research and Innovation (2014–2020), expli-
citly excludes from funding research activities intended to modify the
genetic heritage of human beings that could make such changes
heritable.64 While the European Union left the door open for a possible
review of this exclusion “in the light of scientific advances,” to date no
exceptions have been made.65
Whether research on human germline genome modification is privately
funded and carried out in Italy is unknown, but it is unlikely because
researchers and funders would be under threat of criminal prosecution
under paragraphs 4 and 5 of Article 13 of Law 40/2004.
di medicinali nonché disposizioni per il riordino delle professioni sanitarie e per la dirigenza
sanitaria del Ministero della salute).
63 EURegulation No. 1291/2013 of the European Parliament and of the Council of December 11,
2013 establishing Horizon 2020 – the Framework Programme for Research and Innovation
(2014–2020) and repealing Decision No. 1982/2006/EC (2013) OJ L 347/104.
64 With the sole exception of research relating to cancer treatment of the gonads: EU Regulation
No. 1291/2013, art. 19.
65 Communication from the Commission to the European Parliament, the Council, the
European Economic and Social Committee and the Committee of the regions, “Horizon
2020 interim evaluation: maximizing the impact of EU research and innovation”, COM
(2018) 2 final, (January 11, 2018).
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iv substantive provisions
Having presented the regulatory environment in general terms, it is now
possible to determine if, and to what extent, research using germline modifi-
cation is permitted in the Italian legal system at each step of the research cycle.
1 Basic Research
a Genome Modification in Human Embryos
As we saw, Article 13 of Law 40/2004 provides:
1. Experimentations on human embryos are prohibited.
2. Clinical and experimental research on human embryos is permitted
provided it pursues only therapeutic and diagnostic purposes, aimed at
protecting the health and development of the embryo itself, and where
alternatives are not available.
Although Article 13 of Law 40/2004 is a very ambiguous norm, at least it is
clear it does not allow human germline genome modification basic research
on embryos (paragraph 1). By “basic research,” we mean research done in
laboratory, in vitro, aimed at improving scientific knowledge and “performed
without thought of practical ends.”66 Considering that Law 40/2004 does not
provide a definition of “embryo,” the ban of experimentation contained in
Article 13 possibly includes also zygotes (pre-embryos), which, since 2009,67
can be frozen as part of in vitro fertilization, whenever the physician believes
that the transfer in utero is not compatible with the health conditions of the
woman.68
Article 13.3 explicitly prohibits the production of human embryos
for research or experimentation purposes (as well as human cloning
and the creation of hybrids or chimeras). Moreover, Article 14 prohibits
the removal of embryos.69 Thus, not only supernumerary healthy
66 V Bush, Science: The Endless Frontier (United States Government Printing Office, 1945), c 3.
See also N Roll-Hansen, “Why the Distinction between Basic (Theoretical) and Applied
(Practical) Research is Important in the Politics of Science” (2009) Centre for the Philosophy
of Natural and Social ScienceContingency andDissent in Science Technical Report 04/09, 4
https://pdfs.semanticscholar.org/62f0/dced123c24c7bc89b7d0d72bfcf885634a43.pdf accessed
February 27, 2017).
67 Due to the exception – de facto introduced by Constitutional Court Judgment No. 151/2009 –
to the prohibition of cryopreservation of embryos (n 48).
68 Private communication, Dr. Gianluca Gennarelli, Senior Consultant, responsible person for
medically assisted fertilization procedures at Ospedale Sant’Anna, Turin.
69 Law 40/2004, art. 14.
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embryos70 but even embryos affected by a genetic disorder (which, for
this reason, will not be transferred in utero) are kept in cryopreservation
sine die, since they cannot be destroyed nor used for research. Italian
scientists cannot create embryonic stem cell lines because doing so
requires the destruction of at least one embryo. However, they are not
prohibited from working on imported lines, and they do so.
Such a legal framework not only generates unnecessary hindrances for scientists
who operate in Italy, but it might be also considered as a violation of Article 15 of
ICESCR. In 2017, a communication was submitted to the Committee on
Economic Social and Cultural Rights, raising the question of the compatibility
of the Italian legislation with the right to science guaranteed under the Covenant.
In particular, as far as Article 15 is concerned, Law 40/2004 has been challenged by
a couple of healthy carriers of a serious hereditary disease who could not donate to
science their embryos affected by such a disorder. The applicants argued that, by
prohibiting research on embryos, even those affected by genetic disorders, Law 40/
2004 interferes with scientific progress, slowing down the search for a cure for
various diseases; secondly andconsequently, in doing so,Law 40/2004 violates their
right to enjoy the benefits of scientific progress and its applications and prevents
them from participating in scientific research by donating their embryos affected
by a genetic disorder. The Commitee, however, has declared inadmissible the
communication in relation to this issue, considering that the authors (who have
not claimed the intention to perform themselves any scientific research) cannot be
considered victims of a violation of their freedom of research.71
b Germline Modification in Human Gametes
As far as gametes are concerned, some issues are clearly regulated, while others
remain ambiguous. The prohibition contained in Article 13.3 of Law 40/2004
refers only to the production of embryos for research. Thus, the production of
“artificial” gametes (i.e., gametes derived from pluripotent cells via in vitro
gametogenesis) is permitted in Italy. Basic research on “artificial” and
70 According to the 2015 guidelines on medically assisted procreation, all embryos which are not
immediately transferred in utero have to be frozen and cryopreserved at the centers where the
techniques were carried out and the related charges are borne by the same centers:Ministry of
Health Decree of 1 July 2015, “Guidelines containing indications for medically assisted
procreation procedures and techniques” (Linee guida contenenti le indicazioni delle procedure
e delle tecniche di procreazione medicalmente assistita), 117.
71 Committee on Economic, Social and Cultural Rights,CSA and GP v. Italy, Communication
No. 22/2017, Views adopted by the Committee under the Optional Protocol of the Covenant, 7
March 2019, UN Doc. E/C.12/65/D/22/2017, para 6.19.
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“natural” gametes is also permitted, considering that it is not banned in clear
words unlike the prohibition of experimentations on embryos.
As far as gametes procurement is concerned, the Ministry of Health is work-
ing on a regulation to transpose the relevant EU directives,72 specifying quality
and safety standards for donated human tissues and cells, in the Italian legal
system. The guidelines adopted by the Ministry of Health in 2015, which are
rather directed to couples accessing ART (assisted reproduction technologies)
treatments, are silent as to gametes donors. In case of heterologous fertilization,
they prohibit intended parents from choosing particular phenotypic
characteristics of the donor to avoid illegitimate eugenic selection.73
As it will be recalled, Article 13.3.b of Law 40/2004 prohibits
any form of eugenic selection of embryos and gametes or interventions that,
through selection techniques, manipulation or artificial procedures, aim at
altering the genetic heritage of the embryo or the gamete, or set genetic
features, with the exception of interventions for diagnostic and therapeutic
purposes, as per paragraph 2 of this article.
A key interpretative doubt emerges from the reading of this norm and
concerns the definition of “intervention.” If “intervention” refers exclusively
to clinical activity (i.e., in vivo, on patients), the prohibition of manipulation
does not apply to in vitro research on gametes, and their manipulation is
allowed. This interpretation would be consistent with the way the word
“intervention” is used elsewhere in Law 40/2004, where it is used in the context
of medically assisted reproduction procedures and not research as such.74 It
would be also consistent with the other prohibition listed in the provision,
namely the “selection for eugenic purposes.” It is clear, indeed, that this kind
of selection can be realized only in a clinical activity (i.e., in a medically
assisted reproduction procedure), since the eugenic purpose per se implies the
transfer in utero as it is connected with the potential birth of a new individual.
72 Directive 2004/23/EC of the European Parliament and of the Council of March 31, 2004 on
setting standards of quality and safety for the donation, procurement, testing, processing,
preservation, storage and distribution of human tissues and cells (2004) OJ L 102/48;
Commission Directive 2006/17/EC of February 8, 2006 implementing Directive 2004/23/EC
of the European Parliament and of theCouncil as regards certain technical requirements for the
donation, procurement, and testing of human tissues and cells (2006) OJ L 38/40; Commission
Directive 2006/86/EC ofOctober 24, 2006 implementingDirective 2004/23/EC of the European
Parliament and of the Council as regards traceability requirements, notification of serious
adverse reactions and events, and certain technical requirements for the coding, processing,
preservation, storage, and distribution of human tissues and cells (2006) OJ L294/32.
73 Ministry of Health Decree of July 1, 2015, 113.
74 See arts 2, 4, 10, 15, 16.
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However, Article 13 deals with research and not with clinical activity. For
this reason the term “intervention” might need to be given a special meaning,
different from the one given to it in other sections regulating other stages of
research. If that is the case, the legitimacy of gametes manipulation depends
on whether or not they aremanipulated for therapeutic or diagnostic purposes:
Only manipulation pursuing such aims would be allowed.
Another relevant issue is whether and to what extent mitochondrial manipula-
tion techniques (MMT)75 are permitted under Law 40/2004, considering that
“the transfer of female embryos created via MMT can impact future generations
through the maternal transmission of mtDNA.”76 Preclinical research using
MMT seems to be permitted as long as it concerns oocytes not destined to be
implanted once fertilized. In addition, clinical applications should also be con-
sidered compatible with Article 13, if they aim at protecting the health and
development of the embryo itself. This point is of foremost importance, since in
the near future MMT might be used “to prevent the onset of serious mitochon-
drial diseases in offspring as a reproductive option for prospective parents who
wish to have a genetically related child and who have experienced PGD failure
due to the high load of mtDNA mutations in the oocytes.”77
2 Preclinical Research Using Germline Genome
Modification Technologies
The Legislative Decree No. 26, of March 4, 2014,78 implementing Directive
2010/63/EU on the Protection of Animals Used for Scientific Purposes, impli-
citly allows germline genome modification research on animals.79 In particu-
lar, this conclusion can be derived from the definition of “procedure” detailed
under Article 3.1.a of the Legislative Decree, as
any use, invasive or non-invasive, of an animal for experimental or other
scientific purposes, with known or unknown outcome, or educational
75 “Thus,MMTcan alter themtDNAcontent of human oocytes or zygotes throughCT, karyoplast
transfer (which includes carryover mtDNA) or autologous mitochondrial transfer (which might
undergomutagenesis during preparation) to treat intractable infertility or preventmitochondrial
disease in offspring”: T Ishii and Y Hibino, “Mitochondrial Manipulation in Fertility Clinics:
Regulation and Responsibility” (2018) 5 Reproductive BioMedicine and Society Online 93, 94
https://doi.org/10.1016/j.rbms.2018.01.002 accessed July 31, 2018.
76 Ibid. 95.
77 Ibid. 107.
78 Legislative Decree No. 26/ 2014, “Implementation of Directive 2010/63/EU on the protection
of animals used for scientific purposes” (Attuazione della direttiva 2010/63/UE sulla protezione
degli animali utilizzati a fini scientifici).
79 Directive 2010/63/EU of the European Parliament and of the Council of September 22, 2010
on the protection of animals used for scientific purposes (2010) OJ L276/33.
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purposes, which may cause the animal a level of pain, suffering, distress or
lasting harm equivalent to, or higher than, that caused by the introduction of
a needle in accordance with good veterinary practice. This includes any
action that intends or may lead to a series of genetically modified animals
with a phenotype suffering in these conditions.80
As in any research on animals, limits and conditions are imposed to germline
modification technologies. In particular, animals can be only used for scientific
purposes when no other experimental method or strategy not involving the use of
living animals and that is scientifically valid and reasonably and practically
applicable is available.81 Additionally, in Italy, raising genetically modified ani-
mals is allowed under the authorization of the Ministry of Health, provided the
risks and benefits, the extent to which the manipulation is needed, the possible
impact on the welfare of the animals, and the potential risk for human health,
animal health, and the environment are assessed in advance.82Moreover, specific
provisions apply to research on endangered species (Article 7), nonhuman
primates (Article 8), animals taken from the wild (Article 9), stray and feral
animals of domestic species, including dogs and cats (Article 11).
3 Clinical Research Using Germline Genome Modification Technologies
Clinical research using human germline genome modification is explicitly
prohibited by Legislative Decree No. 211 of June 24, 2003,83 implementing
Directive 2001/20/EC on good clinical practice in the conduct of clinical trials
on medicinal products for clinical use.84 Article 9.6 of the Legislative Decree
requires the “sponsor”85 to obtain written authorization by the Ministry of
80 Also, Art. 17.1 states that “[a] procedure is considered terminated (. . .) when, in the case of new
lines of geneticallymodified animals, transmission of genetic alteration has not given rise to or
is not expected to give rise, with regard to descendants, to a level of pain, suffering, distress or
prolonged injury equivalent or superior to that caused by the insertion of a needle.”
81 Legislative Decree No. 26/ 2014, art 1.2.
82 Ibid., art. 10.4.
83 Legislative DecreeNo. 211 /2003, “Implementation of Directive 2001/20/EC on the application
of good clinical practice in the execution of clinical trials of medicinal products for clinical
use” (Attuazione della direttiva 2001/20/CE relativa all’applicazione della buona pratica
clinica nell’esecuzione delle sperimentazioni cliniche di medicinali per uso clinico).
84 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the
approximation of the laws, regulations, and administrative provisions of the Member States
relating to the implementation of good clinical practice in the conduct of clinical trials on
medicinal products for human use (2001) OJ L121/34.
85 Namely, “an individual, company, institution or organization which takes responsibility for
the initiation, management and/or financing of a clinical trial”: Legislative Decree No. 211/
2003, art 2.3.e.
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Health before the beginning of clinical trials involving the use of gene therapy
but affirms that “trials of gene therapy that lead to changes in the germline
genetic properties of the subject cannot be performed.”86 The provision
replicates almost verbatim Article 9.6 of the Directive 2001/20/EC, which
requires authorization by the competent authority in Member States “before
commencing clinical trials involving medicinal products for gene therapy,
somatic cell therapy including xenogenic cell therapy and all medicinal
products containing genetically modified organisms” and prohibits any gene
therapy trials “which result in modifications to the subject’s germ line genetic
identity.”87
In 2014, the Directive was repealed by EU Regulation 536/2014.88 However,
implementation of EU Regulation 536/2014 depends on the development of
a fully functional EU clinical trials portal and database, which is estimated to
occur in 2020. Echoing the Directive, Article 90 of the Regulation, entitled
“Specific requirements for special groups of medicinal products,” provides
that “no gene therapy clinical trials may be carried out which result in
modifications to the subject’s germ line genetic identity.”
4 Clinical Applications of Germline Genome Modification Technologies
Counterintuitively, Article 13 of Law 40/2004 leaves the door open to clinical
applications of germline modification technologies. As it has been recalled,
Article 13 allows clinical and experimental research on human embryos,
including “selection techniques, manipulation or artificial procedures,
aim[ing] at altering the genetic heritage of the embryo or the gamete, or set
genetic features,”89 provided research “pursues only therapeutic and diagnos-
tic purposes, aimed at protecting the health and development of the embryo
itself, and where alternatives are not available.”90
Although extremely ambiguous, this part of Article 13 ought to be inter-
preted as dealing with clinical applications and not with clinical research as
such. We intend clinical application as referring to approved therapies that
cure embryos from genetic defects and ensure their development. These
therapies would be consistent with the “therapeutic purposes,” on which the
86 Ibid., art. 9.6.
87 Directive 2001/20/EC, art. 9.6.
88 EU Regulation No. 536/2014 of the European Parliament and of the Council of April 16, 2014
on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC
(2014) OJ L 158/1.
89 Law 40/2004, art. 13.3.b.
90 Ibid., art. 13.2.
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provision insists. On the contrary, clinical research remains prohibited, also
considering that, due to the principle of primacy of EU law over domestic
sources referred to above, Article 13 of Law 40/2004 must be interpreted
consistently with the mentioned EU norms (in particular, EU Regulation
536/2014), prohibiting gene therapy trials resulting in modifications to the
subject’s germline.
As such, clinical applications of germline modification technologies are not
prohibited by Law 40/2004.
v current perspectives and future possibilities
For historical, social, and religious reasons, Italy has always been very con-
servative when it comes to life sciences. This exceedingly cautious attitude is
reflected in Law 40/2004, at least in its original version before being chipped
away by the Constitutional Court and ECtHR. Thus, it seems bizarre that Law
40/2004 prohibits basic research and clinical trials of human germline genome
modification but does not prohibit its clinical application. It is probably an
accidental paradox, the result of badly and hastily drafted legislation.
However, it might be a serendipitous omission, one that is consistent with
the overall aim of Law 40/2004: to protect the embryo. Curing it from genetic
diseases would further this goal.
However, given the prevailing attitude among Italian lawmakers, parti-
cularly in the field of life sciences, there are still many doubts about the
concrete possibility that the Ministry of Health might give the green light
to clinical applications that lead to a modification of the human germline
genome. It is also impossible, at present, to define whether these techni-
ques can be considered as medicines – and, therefore, follow the process
that, through the role of Ethical Committees referred to above, termi-
nates with the authorization granted by the Italian Agency for Drugs
(Agenzia Italiana del Farmaco) – or whether they should be classified
differently.
In any event, recent developments and new possibilities in the field of
human germline genome modification call for regulations that, while setting
limits to contain possible abuses, do not wholly frustrate scientific and tech-
nological progress.91 As it has been correctly stated, we are witnessing
“a complex − more implicit than explicit − negotiation process between
91 EM Kane, “Human Genome Editing: An Evolving Regulatory Climate” (2017) 57 Jurimetrics
J. 301.
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science and society taking place regarding which technique should be devel-
oped and used and for which reason this should or could be done.”92
As far as Italy is concerned, considering that the ban on clinical research
using germline modification technologies comes from EU law, the only space
for a normative change concerns basic research applying human germline
genome modification on embryos. This is currently outlawed by Law 40/2004,
but it should be permitted, under certain conditions (such as the informed
consent of people whose gametes have been used). Only the improvement of
basic research on gametes would in fact permit future decisions on whether,
and possible identification of which, clinical applications are scientifically
feasible and ethically acceptable.93 Italy’s prohibition of research on cryopre-
served supernumerary embryos, which, in any case, are not meant to be
implanted and are therefore destined to remain stored sine die, unreasonably
hampers two fundamental rights: the right to science and the right to health.
The approach toward the regulation of human germline genome editing
should also be reconsidered at the international level. So far, concerns for
potential misuses and abuses of human germline genome modification have
determined an extremely cautious attitude toward these technologies, as
illustrated, among other documents, by the Report on Pre-implantation
Genetic Diagnosis and Germline Intervention prepared by the International
Bioethics Committee of UNESCO.94 However, it is paramount to develop
greater awareness of the potential of these scientific innovations and, while
maintaining a high level of attention for possible dangerous drifts, to limit the
constraints to research in this field, with the aim to promote a full realization
of the right to science.
92 M Braun and P Dabrock, “‘I bet you won’t’: The Science-society Wager on Gene Editing
Techniques” (2016) 17:3EMBO reports 279. According to the authors, “[t]he current debate on
gene editing could perhaps be understood as a wager between science and society: one side –
mostly scientists – is trying to guess and cater for the possible reaction of the other side, while
the other side – mostly the public – is trying to discern the underlying intentions and goals of
the other.”
93 D Baltimore and others, “A Prudent Path Forward for Genomic Engineering and Germline
Gene Modification” (2015) 348:6230 Science 36; Italian Committee for Bioethics (ICB),
L’editing genetico (n 53) 15.
94 UNESCO – International Bioethics Committee, “Report of the IBC on Pre-implantation
Genetic Diagnosis and Germ-line Intervention” (2003) SHS-EST/02/CIB-9/2(Rev.3).
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